Merck, Ambrx Partner In Effort To Create Better-Targeted Drug Conjugates

Unlike most work in antibody-drug conjugates, however, the collaboration will not focus on oncology but on a broad array of undisclosed targets that may be applicable in a wide variety of indications.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Platform Technologies

More from Advanced Technologies